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a b s t r a c t
Background: A more affordable pneumococcal conjugate vaccine (PCV) that provides comparable protec-
tion to current PCVs is needed to ensure sustainable access in resource-limited settings. Serum Institute
of India Pvt. Ltd.’s PCV candidate (SIIPL-PCV) has the potential to meet this need as manufacturing effi-
ciency has been optimized and the vaccine targets the most prevalent disease-causing serotypes in
Africa and Asia. We report SIIPL-PCV’s safety, tolerability, and immunogenicity in adults, toddlers, and
infants in The Gambia.
Methods: This phase 1/2, randomized, double-blind trial sequentially enrolled 34 PCV-naive adults (18–
40 years old), 112 PCV (Prevenar 13 [PCV13])-primed toddlers (12–15 months old), and 200 PCV-naive
infants (6–8 weeks old), who were randomized (1:1) to receive SIIPL-PCV or a licensed comparator vac-
cine. Infants received three-doses of SIIPL-PCV or PCV13 at 6, 10, and 14 weeks of age co-administered
with routine Expanded Program on Immunization (EPI) vaccines. Reactogenicity was solicited through
seven-days post-vaccination; unsolicited adverse events (AEs) were assessed throughout the study.
The safety and immunogenicity of a matching booster at 10–14 months of age were evaluated in a subset
of 96 infants. Immune responses were evaluated post-primary and pre- and post-booster vaccinations.
Results: Reactogenicity was primarily mild-to-moderate in severity. In infants, the most common soli-
cited reactions were injection-site tenderness and fever, with no meaningful treatment-group differ-
ences. There were no serious or severe vaccine-related AEs and no meaningful trends in SAEs, vaccine-
related AEs, or overall AEs. Infant post-primary seroresponse rates (IgG level  0.35 mg/mL) were 89%
for all serotypes except 6A (79%) in the SIIPL-PCV group. IgG GMCs were >1 mg/mL for all serotypes in
both SIIPL-PCV and PCV13 groups. Post-booster GMCs were comparable between groups.
Conclusion: SIIPL-PCV was well-tolerated, had an acceptable safety profile, and was immunogenic for all
vaccine serotypes. Results support the evaluation of SIIPL-PCV in a phase 3 non-inferiority trial.
Clinicaltrials.gov: NCT02308540.
 2019 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Streptococcus pneumoniae is the leading cause of severe pneu-
monia worldwide, a condition which, in 2015, caused nearly one
million deaths in children under five years old [1]. Invasive pneu-
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mococcal disease (IPD), including sepsis and meningitis, also
results in high childhood morbidity and mortality, particularly in
low-resource settings [2,3].
Pneumococcal conjugate vaccines (PCVs) are highly effective at
protecting children from IPD and their introduction has substan-
tially reduced morbidity and mortality from pneumococcal disease
in children, including in The Gambia where this study was under-
taken [3–8]. Despite this, the burden of vaccine-preventable pneu-
mococcal pneumonia and IPD remains high in many low-resource
settings related to delayed PCV introduction and low coverage
[2,3]. The high cost of PCVs makes them difficult for low- and
middle-income countries (LMICs) to afford without considerable
financial assistance, and places a high financial burden on coun-
tries graduating from support for vaccine purchase from Gavi,
the Vaccine Alliance [9,10]. Increased access to safe, efficacious,
and affordable PCVs could therefore substantially reduce
pneumococcus-related childhood morbidity and mortality [9,11].
The 10-valent candidate PCV developed by Serum Institute of
India Pvt. Ltd. (SIIPL), SIIPL-PCV, incorporates the most prevalent
IPD-causing serotypes prior to PCV introduction in Africa, Asia,
and Latin America (1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, and 23F). Thus,
the vaccine offers comparable serotype coverage to licensed PCVs
in these settings [12]. Furthermore, SIIPL has lowered SIIPL-PCV’s
manufacturing costs by optimizing three critical components of
the manufacturing process: carrier protein production, polysaccha-
ride production, and conjugation efficiency. Therefore, if SIIPL-PCV
is found to be safe and immunogenic, it will be provided at a con-
siderably lower price than currently licensed PCVs.
This phase 1/2, age de-escalation trial evaluated the safety, tol-
erability (primary objectives), and immunogenicity (secondary
objectives) of SIIPL-PCV compared to the licensed 23-valent pneu-
mococcal polysaccharide vaccine (Pneumovax23, Merck
[PPSV23]) in adults and compared to the 13-valent PCV (Preve-
nar13, Pfizer [PCV13]) in toddlers and infants. Adults and tod-
dlers received a single dose of either SIIPL-PCV or comparator
vaccine while infants received three-doses of either SIIPL-PCV or
PCV13 at 6, 10, and 14 weeks old. In infants, PCV was co-
administered with the routine Expanded Program on Immuniza-
tion (EPI) vaccines. The immune responses to components of co-
administered pentavalent vaccine (diphtheria, tetanus, whole-cell
pertussis, hepatitis B, and Haemophilus influenzae type b [DTwP-
HepB-Hib]), and the safety, tolerability, and immunogenicity of a
booster dose of SIIPL-PCV given to a subset of infants between 10
and 14 months old were also investigated.
2. Methods
2.1. Study design and participants
This was a phase 1/2, parallel-group, randomized, double-blind,
age de-escalation trial conducted by MRC Unit The Gambia—part of
the London School of Hygiene and Tropical Medicine—in clinical
trial facilities in the peri-urban Western region of The Gambia.
Sequential cohorts of 34 PCV-naive adults (18–40 years old), 112
PCV13-vaccinated toddlers (12–15 months old), and 200 PCV-
naive infants (6–8 weeks old) were enrolled starting in January
2015. The last subject completed post-booster follow-up in
November 2016. All toddlers had previously received three-doses
of PCV13 according to the two-, three-, and four-month EPI sched-
ule in The Gambia. All subjects/parents provided written informed
consent prior to the conduct of any trial-related procedures and
were deemed healthy based on defined eligibility criteria
(Table S1). An unblinded data and safety monitoring board
reviewed safety data before vaccination of the next descending
age cohort began. To evaluate immune persistence and the
response to booster vaccination post-priming, the protocol was
amended to include a matching dose of either SIIPL-PCV or
PCV13 to be given at 10 months old to booster-eligible infant
subjects whose parent provided separate consent.
Adults were randomized 1:1 (stratified by sex) to receive a sin-
gle dose of either SIIPL-PCV or PPSV23, while toddlers and infants
were randomized 1:1 to receive either SIIPL-PCV or PCV13 (single
booster dose for toddlers, three-dose primary series for infants).
Randomization sequences were generated using permuted blocks
with randomly selected block sizes by an independent biostatisti-
cian implementing a validated SAS macro. Vaccine assignment
was indicated in individual, sequentially-numbered, sealed, opa-
que, tamper-evident envelopes. Once subject eligibility was con-
firmed, randomization was undertaken by unblinded nurses
using the next envelope in sequence. The same unblinded nurses
prepared and administered all vaccinations in the study but were
not involved in any other subject-related procedures or endpoint
assessments. During the primary study, subjects, parents, and all
study staff except the unblinded nurses were blinded to treatment
assignment. The infant booster phase (added after study unblind-
ing) was single-blinded. The investigator and study clinicians were
unblinded to group assignment but all other site staff, laboratory
personnel, and subjects’ parents remained blinded.
Adults and toddlers underwent four clinic visits (screening, vac-
cination, and follow-up at 7 days [d] and 28d post-vaccination).
Infants underwent up to 11 clinic visits (primary phase: screening,
three vaccination visits 28d apart, each with follow-up visit 7d
post-vaccination, plus two follow-up visits 28d and 84d after the
final vaccination; booster phase: booster vaccination visit,
follow-up visit 28d post-booster) (Fig. 1).
Following each vaccination, trained field workers conducted
daily home visits to solicit injection-site and systemic reactogenic-
ity. Participants were also asked to contact the study team with
any health-related concerns at any time during the study and,
under such circumstances, were seen by a study clinician who pro-
vided treatment or referral if necessary, and recorded all adverse
events (AEs).
A single 0.5 mL dose of SIIPL-PCV contains 2 lg of polysaccha-
ride for serotypes 1, 5, 9V, 14, 19A, 19F, 23F, 7F, and 6A, and 4 lg
for serotype 6B, each individually conjugated to the diphtheria
toxoid-derived recombinant Cross-Reactive-Material 197
(CRM197), with 0.125 mg per dose of aluminum as aluminum phos-
phate. Lot 209E3001 was used throughout. PPSV23 and PCV13
composition has been described previously [13,14]. All study vac-
cines were administered intramuscularly using a 23G 25 mm nee-
dle into the mid-deltoid of the subject’s non-dominant arm in
adults and the mid-thigh in toddlers and infants. DTwP-HepB-
Hib (SIIPL), bivalent oral poliovirus vaccine (SIIPL), and oral rota-
virus vaccine (Rotateq, MSD Vaccines) were co-administered with
all primary doses, and inactivated poliovirus vaccine (SIIPL) was
co-administered with the third dose according to The Gambian
EPI schedule.
The study was conducted in accordance with Good Clinical
Practice and the Declaration of Helsinki, and registered with Clin-
icalTrials.gov (NCT02308540). The Gambia Government/MRC Joint
Ethics Committee, Medicines Board of The Gambia Government,
and Western Institutional Review Board approved the study proto-
col, amendments, and informed consent forms.
2.2. Assessments
Blood samples were collected pre-vaccination and 28d post-
vaccination for adults and toddlers, and pre-vaccination and 28d
post third vaccination for infants. Infants receiving a booster were
bled pre-booster and 28d post-booster. Injection-site and systemic
reactogenicity was solicited in clinic one hour (h) (30 min post-
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booster) and daily for 7d post-vaccination (6d post-booster) and
was severity-graded (one to four) per protocol definitions. Any
ongoing reactogenicity at the end of the follow-up period (e.g., per-
sistent injection-site swelling) was reported as an unsolicited AE
and followed up accordingly. Biochemical and hematological labo-
ratory examinations were undertaken at screening in all cohorts
and 7d post-vaccination in adults and toddlers. Unsolicited AEs
were recorded from consent through 28d (adult and toddler
cohorts) or 84d (infant primary phase) following vaccination. For
infants in the booster phase, AEs were additionally recorded from
the booster visit through 28d post-booster. AEs were categorized
using MedDRA version 17.1 and severity graded from one (mild)
to five (resulted in death) per protocol definitions. Vaccine-
relatedness of systemic reactogenicity and treatment-emergent
AEs (TEAEs) was evaluated by site clinicians. Clinical laboratory
evaluations and vital signs were toxicity-graded per protocol defi-
nitions and assessed for clinical significance by a study clinician.
Immunogenicity was evaluated by the World Health Organiza-
tion (WHO) Pneumococcal Serology Reference Laboratory, Univer-
sity College London, United Kingdom, using a validated enzyme-
linked immunosorbent assay to quantify pneumococcal serotype-
specific immunoglobulin G (IgG) concentrations, and a four-fold
multiplexed opsonophagocytic assay (OPA) to quantify functional
immune responses [15,16]. Seroresponse was defined as a serum
IgG level 0.35 mg/mL, a threshold associated with protection
against IPD in infants; seroresponse based on the functional assay
was defined as a reciprocal OPA titer 8 [17–19]. IgG concentra-
tions were measured in the infant cohort for each component of
the co-administered DTwP-HepB-Hib vaccine at Public Health Eng-
land laboratories, United Kingdom. Seroprotection thresholds for
all pentavalent components except pertussis antigens were
predefined.
2.3. Statistical analysis
The analysis of this phase 1/2 study was descriptive. No hypoth-
esis testing was planned. The sample size of each cohort was cho-
sen to provide sufficient data to support age-de-escalation and,
subsequently, safety and immunogenicity data to support deci-
sions regarding further evaluation of SIIPL-PCV in phase 3 trials.
The sample size of 100 infants per group provided a 90%
chance of observing an AE with a 2.3% occurrence rate. If no AE
occurred, the upper limit of the one-sided 95% confidence interval
(CI) for the occurrence rate was 3.0%. The same sample size pro-
vided >99% power to detect a two-fold difference in geometric
mean concentration (GMC) between groups and >80% power to
detect a 10% lower seroresponse rate following SIIPL-PCV assuming
a 98% seroresponse following PCV13. Although not tested in this
study, these criteria are relevant because they reflect the margins
of immunologic non-inferiority used in previous PCV licensure tri-
als [20,21].
Safety endpoints were injection-site and systemic reactogenic-
ity and TEAEs and were evaluated descriptively.
Immunogenicity endpoints were GMCs or geometric mean
titers (GMTs); geometric mean fold-rise (GMFR), where fold-rise
was calculated as a subject’s later measurement divided by their
earlier measurement; and seroresponse rates. Treatment groups
were compared using GMC ratio, GMT ratio or GMFR ratio (SIIPL-
PCV/comparator), and difference in seroresponse rates (SIIPL-PCV
minus comparator). In the infant cohort, a booster response was
defined by comparing the GMC 28d post-booster with the GMC
28d post-primary series. The GMC post-booster was also compared
with the GMC pre-booster in the toddler and infant cohorts.
The CIs around proportions and differences in proportions were
calculated using exact methods (exact binomial and unconditional
exact method [22], respectively). The CIs around GMCs, etc. were
constructed using t-tests assuming log-normality or, where this
assumption was not met, from bootstrap resampling (10,000 repli-
cates) [23,24].
Subjects who did not complete the study contributed to analy-
ses as available. Immunogenicity assays reported as below the
limit of quantification (LOQ) were assigned a value of one-half
the LOQ; otherwise, no imputation was conducted. Since >80% of
HepB antibody concentrations were reported as >1000 mIU/mL,
Fig. 1. Study design for infant cohort. Infants were vaccinated at between 6 and 8 weeks of age. Screening began from up to 2 weeks before this.1Visits took place at 28–
42 day intervals; 2Solicited injection-site and systemic reactogenicity collected through post-vaccination day 1 to day 6 home visits (HV) plus a day 7 clinic visit; 3Solicited
injection-site and systemic reactogenicity collected through post-vaccination day 1 to day 6 home visits (HV); Safety reporting of unsolicited adverse events.
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the percent exceeding the seroresponse threshold was calculated
but GMCs were not.
3. Results
3.1. Disposition and demographics
All cohorts met recruitment targets and all adults (Fig. 2A) and
toddlers (Fig. 2B) completed the study per protocol. One infant in
the PCV13 group withdrew from the study; therefore, 199 of 200
(99.5%) infants completed the study per protocol (Fig. 2C). A total
of 96 infants (49 SIIPL-PCV, 47 PCV13) received a booster dose of
study vaccine and contributed to the booster analysis (Fig. 2D).
Treatment groups in all cohorts were well-balanced with
respect to age, sex, weight, and height/length (Table 1; adult and
toddler data not shown).
3.2. Safety
3.2.1. Adults
All solicited injection-site and systemic reactogenicity in adults
was mild and resolved within 24–48 h, with no meaningful differ-
ences between treatment groups (data not shown).
Four (23.5%) and 10 (58.8%) adults in the SIIPL-PCV and PPSV23
groups, respectively, had at least one TEAE, most commonly a gas-
trointestinal disorder (11.8% and 35.3% of adults in each group
respectively), all of which were mild or moderate in severity. Five
vaccine-related TEAEs occurred in adults (one in the SIIPL-PCV
group [pain in the axilla] and four in the PPSV23 group), all of
which were mild. No SAEs occurred in adults.
3.2.2. Toddlers
Injection-site tenderness was elicited in comparable propor-
tions between groups (Table S2). Injection-site swelling occurred
in 10.7% of those receiving SIIPL-PCV compared to 1.8% of those
receiving PCV13. All injection-site reactions were mild or moder-
ate, and generally resolved within 24–48 h. Drowsiness was
reported in 10.7% of toddlers who received SIIPL-PCV and was
not reported following PCV13 administration. There were no other
notable differences in systemic reactogenicity between groups.
Systemic reactogenicity was mild to moderate, except for three
events of severe (>39 C–40 C) fever, two of which occurred fol-
lowing PCV13 and one following SIIPL-PCV.
The proportion of toddlers with at least one TEAE was similar
between groups. The most common TEAEs in toddlers were infec-
tions (44.6% SIIPL-PCV, 50.0% PCV13), particularly upper respira-
tory tract infections (URTIs), and gastrointestinal disorders (16.1%
SIIPL-PCV, 10.7% PCV13), including diarrhea (Table S2).
Two toddlers in the SIIPL-PCV group and one in the PCV13
group had a mild or moderate vaccine-related TEAE (mild diarrhea
and moderate rash following SIIPL-PCV). Four severe TEAEs
occurred, including two cases of microcytic anemia in the SIIPL-
PCV group deemed unrelated to vaccination. Two severe SAEs
occurred—one (gastroenteritis) in the SIIPL-PCV group and one
(pneumonia) in the PCV13 group, both of which were deemed
unrelated to vaccination and resolved without sequelae.
3.2.3. Infants
In the infant cohort, no severe solicited injection-site reactions
were reported. One severe fever occurred in each group. One epi-
sode of severe cutaneous rash and one episode of severe irritability
were also reported in the SIIPL-PCV group during the primary
phase of the trial. In the booster phase, two of 49 infants in the
SIIPL-PCV group (4.1%) and one of 47 infants in the PCV13 group
(2.1%) had a severe fever. While the rates of injection-site and sys-
temic reactogenicity after each of the three vaccinations in infants
were somewhat variable, no trends were apparent following either
SIIPL-PCV or PCV13 (Table 2).
Nearly all infants had at least one TEAE (97.0% in the SIIPL-PCV
group versus 96.0% in the PCV13 group). The most common TEAEs
in infants were injection-site reactions related to co-administered
DTwP-HepB-Hib vaccine, and URTIs (Table 3). Ten infants had a
study vaccine-related TEAE (two in the SIIPL-PCV group and eight
in the PCV13 group)—primarily persistent injection-site swelling
(two and seven infants, respectively).
Six infants in the SIIPL-PCV group and two infants in the PCV13
group had an SAE. The only SAE reported in more than two infants
was bronchiolitis (three infants [four events] in the SIIPL-PCV
group and one infant [one event] in the PCV13 group). All SAEs
were deemed unrelated to vaccination and resolved without
sequelae.
The only severe TEAEs reported in more than one infant were
two bronchiolitis events in the SIIPL-PCV infant group. No concern-
ing trends were observed in the frequency of any grade of TEAE.
3.2.4. Additional safety assessments
No noteworthy trends from baseline were observed in vital
signs, physical examination findings or post-vaccination laboratory
examinations.
3.3. Immunogenicity results
3.3.1. Adults
In adults, the serotype-specific IgG GMC ranged from 3.56 mg/
mL (95% CI: 1.89–6.72) for serotype 5 to 48.23 mg/mL (95% CI:
28.87–80.59) for serotype 14 following SIIPL-PCV, and from
3.64 mg/mL (95% CI: 2.41–5.52) for serotype 6A to 44.78 mg/mL
(95% CI: 31.04–64.59) for serotype 14 following PPSV23. The GMCs
were higher following SIIPL-PCV for serotypes 6A and 6B (GMC
ratio 4.69 [95% CI: 2.16–10.20] and 2.22 [95% CI: 1.02–4.84],
respectively) and were higher following PPSV23 for serotypes 1
and 9V (GMC ratio 0.31 [95% CI: 0.15–0.64] and 0.56 [95% CI:
0.34–0.95], respectively). The responses to the remaining six sero-
types were comparable between groups (Table S3).
OPA GMTs were also higher for serotypes 6A and 6B following
SIIPL-PCV (GMT ratio 3.48 [95% CI 1.71–6.37] and 3.15 [95% CI:
1.76–5.61], respectively) and for serotype 1 alone following
PPSV23 (GMT ratio 0.22 [95% CI: 0.07–0.99]) (Table S3).
3.3.2. Toddlers
In PCV13-primed toddlers, the serotype-specific IgG GMCs after
the booster dose of either SIIPL-PCV or PCV13 were comparable
(Table 4). The GMCs ranged from 2.30 mg/mL (95% CI: 1.57–3.72)
for serotype 5 to15.77 mg/mL (95% CI: 11.51–23.96) for serotype
6B following SIIPL-PCV and from 3.35 mg/mL (95% CI: 2.46–5.35)
to 19.16 mg/mL (95% CI: 14.98–30.46) for the same serotypes,
respectively, following PCV13.
There was a substantial booster response for all serotypes in
both groups (Table 4). The GMFRs following SIIPL-PCV ranged from
3.82 (95% CI: 2.48–7.34) for serotype 5 to 9.91 (95% CI: 5.58–22.32)
for serotype 6A. The GMFRs following PCV13 ranged from 3.35
(95% CI: 2.26–5.56) for serotype 14 to 24.17 (95% CI: 17.04–
38.35) for serotype 19A. The GMFR ratios ranged from 0.33 (95%
CI: 0.15–0.77) for serotype 19A to 1.50 (95% CI: 0.78–2.78) for ser-
otype 14 and were higher for serotypes 5, 9V, and 19A following
PCV13 than following SIIPL-PCV.
The OPA GMTs following the booster vaccination in toddlers
were broadly comparable (Table 4). GMT ratios ranged from 0.78
(95% CI: 0.32–1.69) for serotype 9V to 3.21 (95% CI: 1.36–7.44)
for serotype 14. The response to serotype 14 alone was higher in
the SIIPL-PCV group.
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3.3.3. Infants
3.3.3.1. Primary series responses. In infants, the point estimates for
seroresponse rates were >90% for all serotypes following the
three-dose primary series of PCV13 and were >90%, and compara-
ble to PCV13 responses, for 8 of 10 serotypes following the same
SIIPL-PCV schedule (Table 5). The seroresponse rate was 79.0%
Fig. 2. Flow of subjects. aComprises screen failures and eligible subjects screened when cohort recruitment was completed; bAssays undertaken on a randomly selected
subset of subjects; cInfants were eligible if the parent provided additional informed consent and the subject had not already received an additional booster dose of PCV13;
ITT—Intention to treat; PP—Per Protocol; PP Immunogenicity—number of subjects included in the serotype-specific pneumococcal IgG analysis; OPA—number of subjects
included in the OPA analysis; PIP—number of subjects included in the pentavalent interference population.
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(95% CI: 69.7–86.5) against serotype 6A and was 89.0% (95% CI:
81.2–94.4) against serotype 6B following SIIPL-PCV. These rates
were lower than the responses to the same serotypes induced by
PCV13 (6A: 12.0% [95% CI: 21.9–2.0]; 6B: 7.9% [95% CI:
15.8–0.5]).
The point estimates for the serotype-specific IgG GMCs after the
primary series were above 1 mg/mL for all serotypes following both
vaccines. The GMCs ranged from 1.02 mg/mL (95% CI: 0.79–1.32)
for serotype 6A to 4.96 mg/mL (95% CI: 4.06–6.07) for serotype 14
following SIIPL-PCV, and from 1.74 mg/mL (95% CI: 1.49–2.03) for
serotype 5 to 5.38 mg/mL (95% CI: 4.68–6.19) for serotype 19F fol-
lowing PCV13. The GMC were higher following PCV13 for seven
(6A, 6B, 7F, 9V, 19A, 19F, and 23F) of the 10 serotypes (Table 5).
Based on OPA titers, between 93.8% (95% CI: 69.8–99.8) and
100% of infants seroresponded following SIIPL-PCV compared to
between 84.6% (95% CI: 54.6–98.1) and 100% following PCV13. In
both groups, the seroresponse rates based on OPA titers were low-
est against serotype 1 but the responses between groups were
comparable (Table 5).
The serotype-specific OPA GMTs following the primary series
were comparable for the two vaccines for six (1, 5, 6B, 14, 19F,
and 23F) of 10 serotypes. The responses were lower for the four
remaining serotypes following SIIPL-PCV than following PCV13
administration (Table 5).
Table 1
Demographic characteristics of infants.
Characteristic Primary Phase Booster Phase
SIIPL-PCV
N = 100
PCV13
N = 100
SIIPL-PCV
N = 49
PCV13
N = 47
Sex, n (%)
Male 48 (48.0) 51 (51.0) 29 (59.2) 27 (57.4)
Mean (SD) age at vaccination 1 (days) 47.2 (4.0) 47.3 (3.8)
Mean (SD) age at booster vaccination (months) 11.4 (0.8) 11.5 (0.9)
Mean (SD) weight at vaccination 1 (kg) 4.7 (0.5) 4.7 (0.6)
Mean (SD) length at vaccination 1 (cm) 55.3 (1.8) 55.5 (2.0)
Race, n (%)
African 100 (100.0) 99 (99.0) 49 (100.0) 47 (100.0)
Other 0 (0.0) 1 (1.0) 0 (0.0) 0 (0.0)
Ethnic group, n (%)
Mandinka 42 (42.0) 55 (55.0) 23 (46.9) 28 (59.6)
Wolof 18 (18.0) 10 (10.0) 9 (18.4) 2 (4.3)
Fula 12 (12.0) 10 (10.0) 6 (12.2) 5 (10.6)
Jola 12 (12.0) 12 (12.0) 5 (10.2) 3 (6.4)
Serahule 5 (5.0) 3 (3.0) 1 (2.0) 3 (6.4)
Serere 8 (8.0) 5 (5.0) 5 (10.2) 5 (10.6)
Manjago 0 (0.0) 1 (1.0) 0 (0.0) 0 (0.0)
Other 3 (3.0) 4 (4.0) 0 (0.0) 1 (2.1)
SD—standard deviation; n (%)—number (percentage) of participants in a given category.
Table 2
Most common solicited reactogenicity events within 7 days of vaccination in the infant primary and booster phases.
Reactogenicity Event Primary Phase Booster Phase
Vaccination 1 Vaccination 2 Vaccination 3 Booster Dosea
SIIPL-PCV
N = 100
n (%)
PCV13
N = 100
n (%)
SIIPL-PCV
N = 100
n (%)
PCV13
N = 100
n (%)
SIIPL-PCV
N = 100
n (%)
PCV13
N = 100
n (%)
SIIPL-PCV
N = 49
n (%)
PCV13
N = 47
n (%)
Local
Tenderness at injection site 19 (19) 17 (17) 20 (20) 27 (27) 21 (21) 21 (21) 9 (18.3) 11 (23.4)
Induration/swelling at injection site 4 (4) 10 (10) 8 (8) 18 (18) 13 (13) 14 (14) 6 (12.2) 4 (8.5)
Systemic
Temperature (37.5 C) 40 (40) 41 (41) 18 (18) 20 (20) 20 (20) 20 (20) 6 (12.2) 6 (12.7)
Irritability 37 (37) 31 (31) 40 (40) 33 (33) 37 (37) 41 (41) 5 (10.2) 7 (14.9)
Decreased appetite 10 (10) 1 (1) 10 (10) 8 (8) 7 (7) 11 (11) 2 (4.1) 5 (10.6)
n (%)—number (percentage); Number (percent) of subjects with grade 1 reactogenicity event during observation period.
a 6 days follow-up.
Table 3
Most common (5% of subjects in any treatment group) treatment-emergent adverse
events (TEAEs) in infant cohort, primary series.
Preferred Termb SIIPL-PCV
N = 100
na (%)
PCV13
N = 100
na (%)
Subjects with at least 1 TEAE 97 (97%) 96 (96%)
Total TEAEs 414 356
d Upper respiratory tract infection 64 (64.0) 48 (48.0)
d Pentavalent vaccination site local reactionc 66 (66.0) 65 (65.0)
d Tinea infection 31 (31.0) 21 (21.0)
d Diarrhea 29 (29.0) 19 (19.0)
d Conjunctivitis 27 (27.0) 19 (19.0)
d Nasopharyngitis 19 (19.0) 17 (17.0)
d Gastroenteritis 13 (13.0) 10 (10.0)
d Cough 12 (12.0) 7 (7.0)
n (%)—number (percentage); AE—adverse event.
a n reflects number of subjects in group with at least one event.
b TEAE coded using MedDRA version 17.1.
c Swelling, tenderness, erythema.
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3.3.3.2. Booster responses. Prior to the booster vaccination, GMCs
were higher in the PCV13 group for serotypes 5, 7F, 14, and 19A
and higher in the SIIPL-PCV group for serotype 6B, reflecting differ-
ences in the kinetics of immune response between groups for cer-
tain serotypes (Table S4 and Fig. 3).
A substantial booster response was observed for all serotypes
following PCV13 and for all serotypes except serotype 5 following
SIIPL-PCV (Table 6). Comparing GMCs post-booster with GMCs
post-primary immunization, the GMC ratios ranged from 1.13
(95% CI: 0.87–1.44) for serotype 5 to 9.03 (95% CI: 5.92–13.79)
for serotype 6A following SIIPL-PCV and from 1.46 (95% CI: 1.12–
1.89) for serotype 9V to 7.75 (95% CI: 5.49–10.94) for serotype
6A following PCV13. The magnitude of the booster response was
greater for five serotypes (1, 6B, 9V, 19A, and 23F) following
SIIPL-PCV and for serotype 5 following PCV13 (Table 6). Only the
GMC against serotypes 19A and 19F remained higher in the
PCV13 group than in the SIIPL-PCV group following the booster
immunization (GMCR 19A: 0.44 [0.27 – 0.72]; 19F 0.65 [0.43 –
0.99]). Comparing GMCs immediately pre-booster with those
post-booster showed a robust response for all serotypes following
both vaccines (Table S5).
3.3.3.3. Responses to co-administered EPI vaccines. All infants had
IgG concentrations above the defined seroprotective thresholds
for tetanus, diphtheria, and HepB whether the three routine doses
of DTwP-HepB-Hib vaccine were co-administered with SIIPL-PCV
or PCV13. A single infant was below the protective threshold for
Hib following co-administration with PCV13. No meaningful differ-
ences were observed in the GMC to any of the three pertussis anti-
gens, tetanus toxoid, diphtheria toxoid, or Hib between groups
(Table S6). As such, nothing was observed to indicate differential
interference with responses to pentavalent vaccine components
between SIIPL-PCV and PCV13.
4. Discussion
This phase 1/2 trial provides safety, tolerability, and immuno-
genicity data on SIIPL-PCV—a novel 10-valent PCV that contains
serotypes chosen to maximize coverage against pneumococcal dis-
ease in LMICs. It also provides preliminary data to support the co-
administration of SIIPL-PCV with primary EPI vaccines. The study
was completed as planned, with age de-escalation from adults to
toddlers and from toddlers to infants dependent on an indepen-
dent review of safety data from the preceding cohort.
SIIPL-PCV was well-tolerated in all age cohorts, including when
co-administered with EPI vaccines in infants. No noteworthy safety
signals were identified. The rates of injection-site and systemic
reactogenicity following SIIPL-PCV were broadly comparable to
those following the licensed comparator vaccines (PPSV23 in
adults, PCV13 in toddlers and infants) and were consistent with
rates previously reported in trials of the licensed PCVs in infants,
including in The Gambia [21,25–27]. Where numerical
treatment-group differences were apparent, they are likely to
Table 4
Pneumococcal serotype-specific IgG GMCs, GMFR (pre-vaccination to post-vaccination), GMFR ratios and OPA GMTs after a single dose of either SIIPL-PCV or PCV13 in the toddler
per protocol immunogenicity population.
IgG GMC OPA GMT
SIIPL-PCV
N = 17a
PCV13
N = 17a
SIIPL-PCV/
PCV13
SIIPL-PCV
N = 17a
PCV13
N = 17a
SIIPL-PCV/
PCV13
SIIPL-PCV
N = 17a
PCV13
N = 17a
SIIPL-PCV/
PCV13
GMC
(95% CI)b
GMC
(95% CI)b
GMC ratio
(95% CI)b
p-value
GMFR
(95% CI)b
GMFR
(95% CI)b
GMFR Ratio
(95% CI)b
p-value
GMT
(95% CI)b
GMT
(95% CI)b
GMT ratio
(95% CI)b
p-value
1 4.59
(3.90, 5.87)
6.09
(4.51, 10.75)
0.75
(0.51, 1.46)
0.265
5.99
(3.60, 10.95)
6.59
(4.78, 12.25)
0.91
(0.44, 1.89)
0.795
436.31
(348.89, 607.71)
438.14
(231.14, 946.46)
1.00
(0.56, 3.30)
0.992
5 2.30
(1.57, 3.72)
3.35
(2.46, 5.35)
0.69
(0.41, 1.31)
0.206
3.82
(2.48, 7.34)
8.00
(6.45, 12.86)
0.48
(0.28, 0.99)
0.023
1358.22
(885.29, 2222.71)
1148.43
(879.86, 1816.25)
1.18
(0.69, 2.23)
0.576
6A 13.33
(9.62, 22.49)
15.83
(11.64, 26.80)
0.84
(0.51, 1.69)
0.566
9.91
(5.58, 22.32)
12.31
(9.17, 21.85)
0.80
(0.38, 1.99)
0.604
19371.45
(11518.40, 37805.99)
12001.09
(7558.53, 23870.11)
1.61
(0.77, 3.94)
0.247
6B 15.77
(11.51, 23.96)
19.16
(14.98, 30.46)
0.82
(0.53, 1.43)
0.446
7.79
(4.56, 16.25)
9.82
(7.74, 15.98)
0.79
(0.41, 1.77)
0.536
8768.08
(4960.46, 13752.15)
7066.76
(4083.54, 13133.54)
1.24
(0.55, 2.63)
0.587
7F 9.17
(7.42, 12.12)
12.35
(8.83, 19.74)
0.74
(0.48, 1.23)
0.219
6.16
(4.38, 10.66)
8.44
(6.38, 14.79)
0.73
(0.43, 1.46)
0.316
10723.98
(6679.71, 18430.03)
12737.21
(7378.18, 19488.47)
0.84
(0.44, 1.76)
0.628
9V 2.35
(1.57, 3.45)
3.90
(2.58, 6.31)
0.60
(0.34, 1.14)
0.097
4.43
(3.05, 7.44)
9.58
(7.32, 16.31)
0.46
(0.27, 0.91)
0.012
3770.19
(1773.95, 7008.61)
4862.30
(2879.67, 7466.32)
0.78
(0.32, 1.69)
0.546
14 14.55
(8.23, 21.52)
8.28
(6.19, 13.82)
1.76
(0.91, 2.98)
0.071
5.04
(3.28, 7.91)
3.35
(2.26, 5.56)
1.50
(0.78, 2.78)
0.208
8213.23
(3981.89, 15174.75)
2557.27
(1472.91, 4197.18)
3.21
(1.36, 7.44)
0.007
19A 9.76
(6.71, 12.62)
13.68
(6.06, 22.64)
0.71
(0.38, 1.56)
0.344
7.89
(3.98, 16.83)
24.17
(17.04, 38.35)
0.33
(0.15, 0.77)
0.008
1789.98
(512.04, 3884.58)
3780.56
(2172.11, 6633.20)
0.47
(0.12, 1.18)
0.184
19F 9.75
(7.36, 12.75)
12.87
(8.46, 22.39)
0.76
(0.44, 1.32)
0.328
5.73
(2.92, 15.98)
13.26
(8.51, 23.50)
0.43
(0.19, 1.29)
0.085
3036.60
(2016.57, 5666.12)
3371.52
(2038.70, 6441.92)
0.90
(0.44, 1.99)
0.787
23F 6.84
(4.28, 10.54)
10.49
(7.70, 19.64)
0.65
(0.35, 1.25)
0.204
9.67
(5.56, 18.98)
16.54
(11.80, 30.76)
0.58
(0.28, 1.30)
0.173
12415.92
(7356.56, 20760.08)
10517.81
(5019.59, 21439.57)
1.18
(0.53, 3.31)
0.716
IgG GMC – Immunoglobulin G geometric mean concentration; GMFR—geometric mean fold rise; OPA GMT – Opsonophagocytic assay titer geometric mean titer;
CI – confidence interval.
a Assays were conducted on a randomly selected subset.
b 95% CIs estimated from bootstrap resampling.
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Table 5
Pneumococcal serotype-specific IgG seroresponse rates, IgG GMCs, OPA seroresponse rates, OPA GMTs and treatment group differences four weeks after the third primary dose of either SIIPL-PCV or PCV13 in the infant per protocol
immunogenicity population.
IgG GMC OPA GMTa
SIIPL-PCV
N = 100
PCV13
N = 100
SIIPL-PCV vs.
PCV13
SIIPL-PCV
N = 20
PCV13
N = 20
SIIPL-PCV vs.
PCV13
% 0.35
mg/mL
(95% CI)
GMC
(95% CI)
% 0.35
mg/mL
(95% CI)
GMC
(95% CI)
% diffb
(95% CI)
p-value
GMC ratio
(95% CI)
p-value
% 8
(95% CI)
GMT
(95% CI)c
% 8
(95% CI)
GMT
(95% CI)c
% diffb
(95% CI)
p-value
GMT ratio
(95% CI)c p-value
1 99.0
(94.6, 100.0)
2.99
(2.54, 3.52)
100.0
(96.4, 100.0)
3.38
(2.95, 3.86)
1.0
(5.5, 2.8)
1.000
0.89
(0.72, 1.09)
0.255
93.8
(69.8, 99.8)
50.7
(24.9, 109.9)
84.6
(54.6, 98.1)
29.4
(13.9, 80.4)
9.1
(-19.8, 40.6)
0.573
1.72
(0.52, 5.16)
0.353
5 100.0
(96.4, 100.0)
2.09
(1.81, 2.41)
97.0
(91.5, 99.4)
1.74
(1.49, 2.03)
3.0
(1.2, 8.4)
0.246
1.20
(0.97, 1.48)
0.087
95.0
(75.1, 99.9)
113.9
(65.9, 176.6)
95.0
(75.1, 99.9)
104.8
(57.2, 200.4)
0.0
(22.4, 22.4)
>0.99
1.09
(0.48, 2.34)
0.836
6A 79.0
(69.7, 86.5)
1.02
(0.79, 1.32)
91.0
(83.6, 95.8)
1.82
(1.48, 2.25)
12.0
(21.9, 2.0)
0.028
0.56
(0.40, 0.78) 0.001
100.0
(83.2, 100.0)
1243.9
(880.7, 1942.6)
100.0
(82.4, 100.0)
3068.2
(2052.7, 5700.0)
0.41
(0.23, 0.88)
0.007
6B 89.0
(81.2, 94.4)
1.57
(1.23, 2.00)
96.9
(91.1, 99.4)
3.64
(2.90, 4.59)
7.9
(15.8, 0.5)
0.049
0.43
(0.31, 0.60)
<0.001
100.0
(82.4, 100.0)
1530.4
(821.7, 2516.2)
95.0
(75.1, 99.9)
2267.4
(950.0, 3873.7)
5.0
(16.4, 26.9)
>0.99
0.67
(0.32, 2.00)
0.380
7F 97.0
(91.5, 99.4)
2.19
(1.84, 2.61)
100.0
(96.4, 100.0)
3.88
(3.36, 4.49)
3.0
(8.4, 1.2)
0.246
0.56
(0.4, 0.7)
<0.001
100.0
(83.2, 100.0)
876.6
(570.7, 1291.6)
100.0
(83.2, 100.0)
3763.2
(2562.5, 5702.5)
0.23
(0.13, 0.42)
<0.001
9V 94.0
(87.4, 97.8)
1.07
(0.91, 1.26)
97.0
(91.5, 99.4)
2.19
(1.87, 2.56)
3.0
(9.8, 3.3) 0.498
0.49
(0.39, 0.61)
<0.001
100.0
(83.2, 100.0)
197.2
(80.5, 379.5)
100.0
(83.2, 100.0)
752.8
(492.7, 1084.4)
0.26
(0.10, 0.57)
<0.001
14 98.0
(93.0, 99.8)
4.96
(4.06, 6.07)
97.0
(91.4, 99.4)
4.47
(3.48, 5.76)
1.0
(4.4, 6.7)
0.683
1.11
(0.81, 1.53)
0.523
100.0
(82.4, 100.0)
1243.4
(652.1, 2035.0)
94.7
(74.0, 99.9)
1108.0
(410.7, 2306.8)
5.3
(16.2, 28.1)
>0.99
1.12
(0.45, 3.48)
0.822
19A 92.0
(84.8, 96.5)
1.49
(1.22, 1.81)
97.9
(92.7, 99.8)
5.20
(4.22, 6.42)
5.9
(13.1, 0.6)
0.101
0.29
(0.21, 0.38)
<0.001
94.1
(71.3, 99.9)
151.3
(51.7, 252.6)
100.0
(83.2, 100.0)
765.7
(568.6, 928.5)
5.9
(30.8, 14.9)
0.460
0.20
(0.07, 0.34)
<0.001
19F 99.0
(94.6, 100.0)
3.87
(3.25, 4.62)
99.0
(94.6, 100.0)
5.38
(4.68, 6.19)
0.0
(4.5, 4.6)
1.000
0.72
(0.58, 0.90)
0.004
100.0
(83.2, 100.0)
744.9
(580.7, 974.1)
95.0
(75.1, 99.9)
499.0
(223.8, 752.9)
5.0
(15.6, 26.9)
>0.99
1.49
(0.96, 3.77)
0.201
23F 91.0
(83.6, 95.8)
1.56
(1.28, 1.89)
91.0
(91.5, 99.4)
2.68
(2.21, 3.25)
6.0
(13.5, 0.9) 0.134
0.58
(0.44, 0.76)
<0.001
100.0
(83.2, 100.0)
627.3
(294.4, 1040.3)
100.0
(83.2, 100.0)
921.4
(508.1, 1498.6)
0.68
(0.29, 1.47)
0.356
IgG GMC—immunoglobulin G geometric mean concentration; OPA GMT—opsonophagocytic assay geometric mean titer; CI—confidence interval.
a Assays were conducted on a randomly selected subset.
b Difference in treatment-group percentages SIIPL-PCV – PCV13.
c 95% CIs estimated from bootstrap resampling.
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reflect chance events given an absence of consistent trends
between age cohorts or across different vaccine doses in infants,
reflecting the limited sample size of this phase 1/2 trial.
In the adult cohort, the IgG GMCs and OPA GMTs were consis-
tently high four weeks after the administration of a single dose
of either SIIPL-PCV or PPSV23. The responses to serotype 6A and
6B were higher following SIIPL-PCV and the response to serotype
1 was higher following PPSV23. The responses to other serotypes
were comparable. Given the underlying biological differences in
the nature of the immune responses to polysaccharide (PPSV23)
and polysaccharide-conjugate vaccines (SIIPL-PCV) as well as the
different quantities of polysaccharide antigens in the two vaccines,
direct comparison of the serological responses they generate has
some limitations [13,14,28,29]. Data on the protection conferred
by PPSV23 in low-income settings are also limited [30–32]. Fur-
thermore, nasopharyngeal pneumococcal carriage in The Gambia
remains 50% in adults of the age recruited to this trial and may
impact not only natural, but also vaccine-induced serotype-
specific pneumococcal immunity [33–36]. Nonetheless, the adult
data support further assessment of SIIPL-PCV although they should
be interpreted with caution given the small number of subjects
evaluated.
In PCV13-primed toddlers, a substantial booster response to all
serotypes was observed in both treatment groups. The post-
booster vaccination GMCs were comparable between groups. For
three serotypes (5, 9V, and 19A) the magnitude of the booster
response was greater following PCV13 than SIIPL-PCV although
this in part reflected baseline GMCs, which tended to be higher
in the SIIPL-PCV group. As in the adult cohort, the potential impact
of differential past or concurrent nasopharyngeal carriage of given
pneumococcal serotypes on the immune responses generated
should be borne in mind given the limited sample size. Nasopha-
ryngeal carriage of pneumococci in this age-group in The Gambia
is in the region of 90%, including persistent vaccine-type carriage
(e.g., 7F, 19F, and 23F) despite high PCV13 coverage [34,37]. In
addition, the toddlers in this study had all received three priming
doses of PCV13 as part of the Gambian EPI schedule. Few studies
have examined the interchangeability of primary and booster
Fig. 3. Serotype-specific immunoglobulin G geometric mean concentrations (GMCs) post-primary series (>P), pre-booster (<B), 4 weeks post-booster (>B) with either SIIPL-
PCV or PCV13 among infants contributing to booster phase (n = 96). Point estimates and 95% confidence intervals.
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PCV [38,39]. The responses to boosting with the licensed 10-valent
PCV (Synflorix, GlaxoSmithKline) following PCV13 priming have
been shown to be generally lower than the responses to boosting
with PCV13 [38]. These differences, however, may have been
explained by the different carrier protein (Haemophilus influenzae-
derived protein D) conjugated to the affected serotypes in the
licensed 10-valent vaccine. Therefore, any role of the different
priming vaccine in the somewhat lower responses to SIIPL-PCV,
which uses the same CRM197 carrier as PCV13, is unclear.
Data from the infant cohort were intended to inform the deci-
sion to advance to a pivotal phase 3 trial designed to demonstrate
that SIIPL-PCV meets the product specifications required of a
licensed and prequalified PCV as detailed in WHO guidance [40].
The guidance specifies that post-primary non-inferiority to a
licensed PCV must be demonstrated, based on either seroresponse
rates or IgG GMCs.
The seroresponse rates following a three-dose primary series of
SIIPL-PCV were above 90% for all except two serotypes. The point
estimate for the difference in the seroresponse rates following
SIIPL-PCV compared to PCV13 was below the 10% non-
inferiority margin used in previous PCV licensure trials for serotype
6A alone [20,21]. While generally higher in the PCV13 group, IgG
GMCs following SIIPL-PCV were above 1 mg/mL for all 10 serotypes,
and the point estimate for the GMC ratio comparing SIIPL-PCV with
PCV13 was below the 0.5 non-inferiority margin used in previous
trials for only three serotypes (6B, 9V, and 19A) [20,21]. Further-
more, the percentage of subjects with functional OPA antibodies
(titer 8) was above 93%, and was similar between the two groups,
for all 10 serotypes. In particular, the immune responses to three
serotypes (6B, 19F, and 23F) that were lower in the SIIPL-PCV
group based on IgG GMCs were similar between groups based on
OPA GMTs. Data have suggested that OPA titers may ultimately
correlate better with estimates of vaccine effectiveness than IgG
concentrations, and high vaccine effectiveness has been demon-
strated against disease endpoints despite generally lower IgG
GMC than reported here [41–43]. Thus, while the responses gener-
ated following the SIIPL-PCV primary series tended to be some-
what lower than those generated following the PCV13 primary
series, they were considered to be robust with both vaccines. The
effects of past or concurrent carriage should again be borne in
mind although, given the double-blind, randomized design, are
likely to become less important as the group size increases.
Comparing GMCs post-booster vaccination with the GMCs post-
primary series, there was a booster response to all serotypes except
serotype 5 following SIIPL-PCV. The lack of booster response to ser-
otype 5 reflected, at least in part, the relatively higher IgG GMC to
this serotype in the SIIPL-PCV group following the primary immu-
nization series, as the post-booster IgG GMCs for this serotype
were comparable between the SIIPL-PCV and the PCV13 groups.
Also, there was a substantial GMFR in antibody responses from
Table 6
Pneumococcal serotype-specific IgG GMCs four weeks after a booster dose of either SIIPL-PCV or PCV13 and IgG GMC ratios (post-boost GMC/post-primary GMC) in the infant
booster per protocol immunogenicity population.
IgG GMC post boost IgG GMC booster response
SIIPL-PCV
N = 48
PCV13
N = 47
SIIPL-PCV/
PCV13
SIIPL-PCV
N = 48
PCV13
N = 47
SIIPL-PCV/
PCV13
GMC
(95% CI)
GMC
(95% CI)a
GMC ratio
(95% CI)
p-value
GMC ratioa
(95% CI)b
GMC ratioa
(95% CI)b
Ratio of GMC ratio
(95% CI)
p-value
1 6.24
(4.35, 8.94)
5.11
(3.76, 6.94)
1.22
(0.77, 1.95)
0.398
2.38
(1.80, 3.14)
1.58
(1.22, 2.04)
1.50
(1.04, 2.19)
0.033
5 2.30
(1.80, 2.93)
2.57
(2.02, 3.26)
0.90
(0.64, 1.25)
0.516
1.13
(0.87, 1.46)
1.77
(1.35, 2.30)
0.64
(0.44, 0.92)
0.016
6A 9.50
(6.53, 13.82)
12.06
(9.61, 15.12)e
0.79
(0.51, 1.22)
0.277
9.03
(5.92, 13.79)
7.75
(5.49, 10.94)
1.17
(0.68, 2.00)
0.574
6B 12.72
(9.29, 17.43)
14.06
(11.11, 17.79)
0.91
(0.61, 1.34)
0.611
9.01
(5.79, 14.03)
3.69b
(2.55, 5.33)
2.45
(1.38, 4.35)
0.003
7F 6.76
(5.26, 8.67)
8.51
(6.80, 10.65)
0.79
(0.57, 1.11)
0.172
3.43
(2.64, 4.46)
2.48
(1.92, 3.20)
1.38
(0.96, 1.98)
0.077
9V 2.44
(1.95, 3.07)
3.23
(2.67, 3.91)
0.76
(0.56, 1.01)
0.062
2.29
(1.80, 2.90)
1.46
(1.12, 1.89)
1.57
(1.11, 2.22)
0.012
14 8.16
(5.86, 11.38)
7.60
(5.52, 10.47)
1.07
(0.68, 1.69)
0.757
1.86
(1.38, 2.50)
2.05
(1.33, 3.15)
0.91
(0.54, 1.52)
0.710
19A 6.72
(4.57, 9.86)
15.20
(11.25, 20.54)
0.44
(0.27, 0.72)
0.001
4.83
(3.43, 6.81)
3.02c
(2.33, 3.90)
1.60
(1.05, 2.45)
0.030
19F 7.73
(5.66, 10.56)
11.85e
(8.99, 15.62)
0.65
(0.43, 0.99)
0.043
2.15
(1.56, 2.95)
2.61d
(1.96, 3.47)
0.82
(0.54, 1.26)
0.364
23F 5.11
(3.73, 7.01)
5.28
(3.83, 7.27)
0.97
(0.62, 1.51)
0.886
3.80
(2.80, 5.17)
2.42
(1.78, 3.27)
1.57
(1.03, 2.41)
0.037
IgG GMC – Immunoglobulin G geometric mean concentration.
a IgG GMC post-booster/IgG GMC post-primary series for subjects with evaluable data at both time points.
b N = 43.
c N = 46.
d N = 44.
e N = 45.
408 E. Clarke et al. / Vaccine 38 (2020) 399–410
pre- to post-booster vaccination for all serotypes in both groups.
While the IgG GMCs following the primary immunization series
were higher for six serotypes following PCV13, these differences
tended to be reduced or even reversed pre-booster, and addition-
ally reduced post-booster. Only the IgG GMC to serotypes 19A
and 19F remained higher in the PCV13 group post-booster.
Serotype-specific differences between PCV13 and SIIPL-PCV in
the kinetics of the immune response have been observed between
PCV13 and the licensed 10-valent vaccine in other studies and war-
rant further assessment [44]. These observations highlight the
importance of assessing not only the primary response, but also
antibody persistence and boosting as part of PCV evaluation.
The study has several important strengths. The integrated phase
1/2 age de-escalation design minimized logistical delay and
ensured robust safety and immunogenicity data were generated
in six-week-old infants to guide further vaccine development in a
timely manner. The infant 6-, 10-, and 14-week schedule is in
keeping with the requirements of the Target Product Profile for
the Advanced Market Commitment for PCV, which sets out the
specifications that new vaccines must meet to secure future pur-
chase for Gavi-eligible countries [41]. The inclusion of an addi-
tional dose of the vaccine given between 10 and 14 months of
age, and blood sample collected pre-booster, allowed both anti-
body persistence and booster response to be assessed. Further-
more, not only IgG but also functional antibodies were measured.
The high per protocol follow-up and completion rates lend confi-
dence in the results and ensured the maximum value of the study
design was realized. Finally, reported differences in response to
PCVs between high- and low-income countries, which may reflect
differences in pneumococcal carriage rates or particular host fac-
tors [40], may limit the generalizability of studies conducted out-
side the target regions. Thus, undertaking the study in The
Gambia, a low-income country in West Africa, ensures that the
data are directly applicable to settings that stand to benefit from
a vaccine such as SIIPL-PCV in the future.
The study limitations are largely those inherent in any early-
phase trial. The analysis is primarily descriptive. Where differences
do exist, they should be interpreted with caution given there was
no accounting for multiplicity. Similarly, the study was not suffi-
ciently powered to confidently exclude differences between groups
where these were not shown. The provisos present in the interpre-
tation of the findings are as expected and will be addressed in
future phase 3 trials.
5. Conclusions
The safety, tolerability and immunogenicity data generated
support the future evaluation of SIIPL-PCV in a phase 3, non-
inferiority, licensure trial in infants.
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